Lynparza® (olaparib)
for Ovarian Cancer
Lynparza (olaparib) is a targeted therapy used to treat certain types of ovarian, breast, fallopian tube, pancreatic, prostate, and peritoneal cancers, particularly those with BRCA1, BRCA2, HRR, or HER2-negative genetic markers. It belongs to a class of medicines called PARP inhibitors, which block the PARP protein that cancer cells rely on for DNA repair. By preventing this repair, Lynparza helps stop cancer cells from surviving and multiplying.
